meta
|
evidence
COVID-19
Living systematic review and meta-analysis
***** adjuvant therapies
anti-inflammatoty and immuno-therapy
Immunostimulants drugs
anti-PD-1 antibody
CD24Fc
convalescent plasma treatment
Early convalescent plasma.
immunoglobulin therapy
inactivated mycobacterium vaccine
interferon
Interleukin-2
levamisole
neutralizing antibody
rhG-CSF
***** antiandrogenic
***** antiviral and associated therapy
***** control
***** Drugs for acid related disorders
***** miscellaneous
***** Oral antidiabetic drugs
***** Renin-angiotensin-system-acting agents
***** vaccines
***** Vitamins
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
secondary prevention
Meta-analysis results for all treatments
Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE).
method
Treament
Trials
Summary
Endpoints
death D28
deaths
deaths (time to event analysis only)
clinical deterioration
clinical improvement
clinical improvement (time to event analysis only)
death or ventilation
hospitalization
mechanical ventilation
viral clearance
viral clearance by day 7
serious adverse events
core analysis (OBS if no RCT)
RCTs only
all (RCT+OBS)
clinical deterioration
clinical improvement
deaths
viral clearance